BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Related Posts
09Sep
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more
01Mar
Privo receives a $2M Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more
01Jan
Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more
04Feb
Privo Technologies, Inc. To Present at the 24th Annual BIO CEO & Investor Conference
Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
20Aug
Privo Technologies, Inc. Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant
Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more
02Dec
Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors
Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more
13Sep
Privo receives Commercialization Award from the National Cancer Institute
Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more
26Jan
Privo Technologies Successfully Completes Phase 1/2 Study of PRV211 Intraoperative Chemotherapy for Head and Neck Cancer Patients Novel Surgical Innovation Demonstrates Excellent Safety Profile with Potential to Reduce Tumor Recurrence
BOSTON, January 23, 2026 – Privo Technologies, Inc. today announced the successful completion of its Phase 1/2 clinical evaluation of... read more
21Mar
Privo Technologies Inc. Announces the Launch of BeneVet Oncology: Advancing Companion Animal Health Through Innovation
Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud... read more
30Jun
Privo Technologies Announces the Appointment of Dr. James Mackay to Its Board of Directors
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more
- © UX Strategy & Digital Branding
